Lilly’s RET inhibitorRET inhibitor wins accelerated approval in paediatric cancers

29 May 2024
·
Deals
firstwordpharma.com
Clinical ResultDrug ApprovalAcquisitionAccelerated Approval
The FDA on Wednesday granted Eli Lilly’s selective RET kinase inhibitor Retevmo (selpercatinib) accelerated approval to treat children two years and older with certain RET-mutated thyroid and solid tumours. According to the US regulator, it’s the first targeted cancer therapy for paediatric patients younger than 12 with RET alterations.
Specifically, Retevmo was cleared for advanced or metastatic medullary thyroid cancer with a RET mutation; advanced or metastatic thyroid cancer with a RET gene fusion in patients who are radioactive iodine-refractory; and locally advanced or metastatic solid tumours with a RET gene fusion in patients who have progressed on a prior systemic therapy.
The RET inhibitorRET inhibitor already holds accelerated approval for the thyroid cancer indications in adults and paediatric patients older than 12, as well as the solid tumour indication in adults.
Supporting data
The new paediatric approval was based on results of the Phase I/II LIBRETTO-121 study in 25 patients ages 2 to 20 with locally advanced or metastatic RET-activated solid tumours non-responsive to available therapies.
Retevmo led to a confirmed overall response rate (ORR) of 48%. Additionally, the median duration of response (DOR) was not reached, with 92% of responders still seeing a treatment effect at 12 months.
The most common adverse reactions seen in more than a quarter of patients were musculoskeletal pain, diarrhoea, headache, nausea, vomiting and fatigue, among others.
Lily gained Retevmo through its $8-billion acquisition of Loxo Oncology in 2019.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.